BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 34057656)

  • 1. CRISPR-Based Genome Editing as a New Therapeutic Tool in Retinal Diseases.
    Rasoulinejad SA; Maroufi F
    Mol Biotechnol; 2021 Sep; 63(9):768-779. PubMed ID: 34057656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Let There Be Light: Gene and Cell Therapy for Blindness.
    Dalkara D; Goureau O; Marazova K; Sahel JA
    Hum Gene Ther; 2016 Feb; 27(2):134-47. PubMed ID: 26751519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome Surgery and Gene Therapy in Retinal Disorders.
    Chan L; Mahajan VB; Tsang SH
    Yale J Biol Med; 2017 Dec; 90(4):523-532. PubMed ID: 29259518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene editing prospects for treating inherited retinal diseases.
    Benati D; Patrizi C; Recchia A
    J Med Genet; 2020 Jul; 57(7):437-444. PubMed ID: 31857428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR-Cas systems: ushering in the new genome editing era.
    Perez Rojo F; Nyman RKM; Johnson AAT; Navarro MP; Ryan MH; Erskine W; Kaur P
    Bioengineered; 2018; 9(1):214-221. PubMed ID: 29968520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome editing: the road of CRISPR/Cas9 from bench to clinic.
    Eid A; Mahfouz MM
    Exp Mol Med; 2016 Oct; 48(10):e265. PubMed ID: 27741224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR-Cas9 in genome editing: Its function and medical applications.
    Khadempar S; Familghadakchi S; Motlagh RA; Farahani N; Dashtiahangar M; Rezaei H; Gheibi Hayat SM
    J Cell Physiol; 2019 May; 234(5):5751-5761. PubMed ID: 30362544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9 gene-editing strategies in cardiovascular cells.
    Vermersch E; Jouve C; Hulot JS
    Cardiovasc Res; 2020 Apr; 116(5):894-907. PubMed ID: 31584620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of AAV Vectors for CRISPR-Mediated In Vivo Genome Editing in the Retina.
    Yu W; Wu Z
    Methods Mol Biol; 2019; 1950():123-139. PubMed ID: 30783971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering the Delivery System for CRISPR-Based Genome Editing.
    Glass Z; Lee M; Li Y; Xu Q
    Trends Biotechnol; 2018 Feb; 36(2):173-185. PubMed ID: 29305085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. INDEL detection, the 'Achilles heel' of precise genome editing: a survey of methods for accurate profiling of gene editing induced indels.
    Bennett EP; Petersen BL; Johansen IE; Niu Y; Yang Z; Chamberlain CA; Met Ö; Wandall HH; Frödin M
    Nucleic Acids Res; 2020 Dec; 48(21):11958-11981. PubMed ID: 33170255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.
    Marsh S; Hanson B; Wood MJA; Varela MA; Roberts TC
    Mol Ther; 2020 Dec; 28(12):2527-2539. PubMed ID: 33171139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vivo CRISPR/Cas9 Gene Editing Corrects Retinal Dystrophy in the S334ter-3 Rat Model of Autosomal Dominant Retinitis Pigmentosa.
    Bakondi B; Lv W; Lu B; Jones MK; Tsai Y; Kim KJ; Levy R; Akhtar AA; Breunig JJ; Svendsen CN; Wang S
    Mol Ther; 2016 Mar; 24(3):556-63. PubMed ID: 26666451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Genome Editing and In Vivo Delivery.
    Ramirez-Phillips AC; Liu D
    AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome Editing of Rat.
    Kaneko T
    Methods Mol Biol; 2023; 2637():223-231. PubMed ID: 36773150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene editing and CRISPR in the clinic: current and future perspectives.
    Hirakawa MP; Krishnakumar R; Timlin JA; Carney JP; Butler KS
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32207531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene and Induced Pluripotent Stem Cell Therapy for Retinal Diseases.
    Maeda A; Mandai M; Takahashi M
    Annu Rev Genomics Hum Genet; 2019 Aug; 20():201-216. PubMed ID: 31018110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas9-Mediated Genome Editing as a Therapeutic Approach for Leber Congenital Amaurosis 10.
    Ruan GX; Barry E; Yu D; Lukason M; Cheng SH; Scaria A
    Mol Ther; 2017 Feb; 25(2):331-341. PubMed ID: 28109959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivering SaCas9 mRNA by lentivirus-like bionanoparticles for transient expression and efficient genome editing.
    Lu B; Javidi-Parsijani P; Makani V; Mehraein-Ghomi F; Sarhan WM; Sun D; Yoo KW; Atala ZP; Lyu P; Atala A
    Nucleic Acids Res; 2019 May; 47(8):e44. PubMed ID: 30759231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice.
    El Refaey M; Xu L; Gao Y; Canan BD; Adesanya TMA; Warner SC; Akagi K; Symer DE; Mohler PJ; Ma J; Janssen PML; Han R
    Circ Res; 2017 Sep; 121(8):923-929. PubMed ID: 28790199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.